91�Թ�

A new partnership between the 91�Թ� and the  seeks to reimagine how high-quality, digital approaches to heart failure can be equitably delivered to all Canadians.  

 will build, support and fund a community of multidisciplinary engineers, basic and data scientists, clinicians and health experts to develop solutions that will help monitor and proactively treat people with heart failure in their own homes and empower them toward greater self-care.  

New therapies are dramatically improving quality of life and survival in heart failure, and technology is capable of changing how the disease is managed, says Heather Ross, a professor in the Temerty Faculty of Medicine and scientific lead at the Ted Rogers Centre. 

“Unfortunately, these therapies and approaches are underutilized and inaccessible to a lot of Canadians. Our goal is to unite the right people in devising new medical and artificial intelligence technologies that will achieve equitable access to high-level care across our country’s vast geography.”  

Heart failure affects at least one million Canadians, statistics show. Nine out of 10 die within 10 years, having experienced a reduced quality of life, frequent lengthy hospital stays, and chronic disruptions to jobs, relationships and family life.  

Ross is co-leading TRANSFORM-HF with Craig Simmons, a professor in the department of mechanical and industrial engineering in the Faculty of Applied Science & Engineering and the Institute for Biomedical Engineering.

“We will bring together the vast amount of technology developed at the 91�Թ� and deploy it in new ways,” says Simmons, who is also a Ted Rogers Centre scientific lead and director of the Translational Biology and Engineering Program. “Our engineers and scientists will help our clinical partners deliver expert care to remote locations and perform continuous monitoring to keep people with heart failure safe.”  

He says some of these innovations, including biosensors and remote monitoring tools, already exist, while others will be co-designed by experts in different fields, and by patients themselves.  

“Technology is often developed in a bubble, so for our engineers and scientists to collaborate with patients on design will change everything,” says Simmons. “The ability to interact with end users early will help us create solutions that work more quickly and more smoothly.” 

“In medicine we must do things with patients, not to patients,” adds Ross. “They are the ones who will use these technologies. They can tell us if our ideas make sense, or how they can be tweaked.”  

A key goal of the program is to build user-centered technology that can be adapted by any patient, in any environment, with any specific need.  

The TRANSFORM HF team will devise a new era of biosensors that can be packaged and used by Canadians in any community. These include wearable sensors built into fabric – socks, patches, vests – that monitor clinically relevant vitals like heart rate, blood pressure, breathing patterns and fluid accumulation. They may include a mobile app that makes use of a special camera to assess blood flow below the skin, and tech that syncs with consumer products like the Apple Watch or Fitbit.  

Simmons says the team will also conceive new ways of bringing diagnostics that are done in the lab to people’s homes.

“Patients often have to travel for them and wait days for results,” he says. “What if we could give them a small device that, for instance, takes a pinprick of blood, runs a test and produces results in 15 minutes? These microtechnologies already exist, but they haven’t been engineered to specifically focus on markers important for heart failure.” 

Such innovations can yield oceans of data, which may hold new signals that reveal the state of someone’s heart failure or the risk of it worsening. The machine learning component of TRANSFORM HF is about creating algorithms that can predict someone’s risk of hospitalization, and enabling clinicians to intervene early to help keep that person in a stable condition. 

TRANSFORM HF plans on training graduate students, scientists and clinicians across disciplines, beyond the lab and in communities and homes where their innovations are to be used.  

“An immersive training experience allows our students to see first-hand what the constraints are, what power is available, what internet connectivity is like, and who the people are that they are designing technology for,” says Simmons. “New innovations will be set up to make a true difference in people’s lives.”  

This training also includes commercialization, as students and fellows will explore entrepreneurship and vital aspects of translating technology such as regulatory rules. 

All of this will rely on brand new partnerships with patients and communities at all stages of development.   

“This is a special opportunity to co-create and test new inventions in a collaborative sandbox, and I expect it to build into a long-term funding model to create a pipeline of innovations in the heart failure space,” Simmons says.  

“For decades, we’ve watched heart failure care evolve incrementally,” says Ross. “But with all stakeholders working together, we will generate ideas that allow for transformative changes in how we manage this complex disease.

“Instead of taking steps we can make leaps.”